Pipeline
Transforming the treatment of disease with highly selective therapeutic antibodies.
Existing therapeutics indiscriminately kill both healthy and diseased cells
Unlocking killing selectivity through avidity
The biological mechanism that we’ve used to achieve killing selectivity is based on the principle of avidity. By harnessing avidity-driven selectivity, our optimised T-cell engagers are able to differentiate between a healthy and diseased cell based on differential TAA expression.
Conventional methods marginally widen therapeutic windows
LabGenius’ approach delivers complete on/off killing selectivity
Modality
Development Stage
Target Selection
Lead Discovery
Lead Optimisation
IND-enabling
Clinical Phase 1
Modality:
LGTX-101
Nectin-4 is a tumour-associated antigen (TAA) that is commonly overexpressed on numerous solid tumour types, including urothelial, head and neck, and triple-negative breast cancer. Nectin-4 is also expressed at low levels on normal, healthy tissues, which limits current ADC therapies due to high rates of dose-limiting, on-target, off-tumour toxicities. This highlights a need for alternative approaches for anti-cancer therapeutics that can selectively target Nectin-4 expressing solid tumours.
Through the tight integration of high-throughput functional cell-based experimentation with machine learning (ML), LabGenius’ proprietary lead optimisation platform (EVA™) generated a highly selective and potent trivalent VHH-based Nectin-4 x CD3 T-cell engager (TCE), LGTX-101. By harnessing avidity-driven selectivity, LGTX-101 is able to differentiate between healthy and diseased cells based on differential TAA expression, demonstrating >70,000-fold killing selectivity in a T-cell-mediated tumour cell killing assay. LGTX-101 is highly efficacious in vivo with complete tumour regression observed in all tumour-bearing mice treated with our lead candidate.
